# Wegovy

Type: Product

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/wegovy
Canonical HTML page: https://getlegalbrief.com/entity/wegovy

## Timeline

- **2026-07-21**: Lawsuit filed — Novo Nordisk sues Eli Lilly in federal court, alleging misleading advertising.
- **2026-04**: Cease-and-desist letter — Novo Nordisk sends a formal request to Eli Lilly to stop running or correct certain ads.
- **2026-03**: High-dose Wegovy approved — Novo Nordisk’s high-dose obesity injection enters the market, achieving weight loss more comparable to Zepbound.

## Recent coverage (1 stories)

### Novo Nordisk sues Eli Lilly under Lanham Act over 2-year-old GLP-1 ad claims
2026-07-21 22:05:06 · Sentiment: Bearish · Impact: 7/10 · Sources: 2

Novo Nordisk alleges Eli Lilly’s comparative advertising for Zepbound relies on outdated clinical data, violating the Lanham Act. The case could redefine how quickly pharma competitors must update ad claims when new drug formulations enter the market.
Full story: https://getlegalbrief.com/story/novo-sues-lilly-misleading-glp1-ads-lanham-act

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.